Integra LifeSciences (IART) announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providing patients with neurosurgical care. Prior to joining Integra, Dr. Turner held various leadership roles at Siemens Healthineers, including his most recent position as the chief medical officer for Siemens Endovascular Robotics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences Earnings Call: Mixed Sentiments and Future Outlook
- Integra LifeSciences Reports Q2 2025 Financial Results
- Integra LifeSciences backs FY25 adjusted EPS view $2.19-$2.29, consensus $2.24
- Integra LifeSciences reports Q2 adjusted EPS 45c, consensus 43c
- Integra LifeSciences sees Q3 adjusted EPS 40c-45c, consensus 58c